Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Treatment every 4 weeks for total of 8-week treatment period.”In the company’s words, NCT06826196 on ClinicalTrials.gov
- Tested for
- Alopecia Areata (AA)
- Main trialPhase 1/2
- “The goal of this first-in-human clinical trial is to learn if ALD-102 Solution is safe and well tolerated following injections in the scalp in subjects with alopecia areata. The study will also learn about the effect of ALD-102 on hair regrowth in treatment areas. The researchers will compare the effects of ALD-102 Solution (drug) to placebo (saline solution that contains no drug) or an untreated area. Study participants will have treatment areas selected on the scalp to receive ALD-102 Solution (drug), placebo (saline solution) or to remain untreated. Injections will occur once every 4 weeks…”In the company’s words, NCT06826196 on ClinicalTrials.gov
Other drugs for Alopecia Areata (AA)
- RitlecitinibPfizer · Phase 3
- DeuruxolitinibSun Pharma · Phase 3
- UpadacitinibAbbVie · Phase 3
- SYHX1901CSPC · Phase 2
- LAD603Almirall, S.A. · Phase 2
- LY4005130Eli Lilly · Phase 2
Coming up1
- NovPhase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | Nov 2026 | A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026